Lymph Node Imaging in Gynecologic Malignancy

Seminars in Ultrasound, CT and MRI

Volumn 31, Issue 5, 2010, Pages 363-376

  Lai, Gillian ^a   Rockall, Andrea G ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; DEXTRAN; FLUORO 3' DEOXY 3 LEVO FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; IRON OXIDE; METHIONINE C 11; NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG COATING; DRUG DELIVERY SYSTEM; FEMALE GENITAL TRACT TUMOR; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; INTERMETHOD COMPARISON; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHOGRAPHY; LYMPHOSCINTIGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TUMOR RECURRENCE; TUMOR VOLUME; ULTRASOUND;

CONTRAST MEDIA; DEXTRANS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; GENITAL NEOPLASMS, FEMALE; HUMANS; IMAGE ENHANCEMENT; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; NANOPARTICLES; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 77958160037     PISSN: 08872171     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sult.2010.07.006     Document Type: Article

References (106)

1. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 2009, 105:103-104.
2. Hertel H., Kohler C., Elhawary T., et al. Laparoscopic staging compared with imaging techniques in the staging of advanced cervical cancer. Gynecol Oncol 2002, 87:46-51.
3. Schlaerth J.B., Spirtos N.M., Carson L.F., et al. Laparoscopic retroperitoneal lymphadenectomy followed by immediate laparotomy in women with cervical cancer: A gynecologic oncology group study. Gynecol Oncol 2002, 85:81-88.
4. Franchi M., Ghezzi F., Riva C., et al. Postoperative complications after pelvic lymphadenectomy for the surgical staging of endometrial cancer. J Surg Oncol 2001, 78:232-237.
5. Bidus M.A., Elkas J.C. Cervical and vaginal cancers. Berek and Novak's Gynecology 2007, Lippincott Williams & Wilkins, Philadelphia. J.S. Berek (Ed.).
6. Fuller A.F., Elliott N., Kosloff C., et al. Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix. Gynecol Oncol 1989, 33:34-39.
7. Tsai C.S., Lai C.H., Wang C.C., et al. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy. Gynecol Oncol 1999, 75:328-333.
8. Chan J.K., Kapp D.S., Cheung M.K., et al. The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. Br J Cancer 2007, 97:605-611.
9. Watari H., Todo Y., Takeda M., et al. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer. Gynecol Oncol 2005, 96:651-657.
10. Ghurani G.B., Penalver M.A. An update of vulvar cancer. Am J Obstet Gynecol 2001, 185:294-299.
11. Ovarian Cancer. American Cancer Society Accessed August 2, 2010. http://www.cancer.org.
12. Landoni F., Maneo A., Colombo A., et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997, 350:535-540.
13. Fiorica J.V., Roberts W.S., Greenberg H., et al. Morbidity and survival patterns in patients after radical hysterectomy and postoperative adjuvant pelvic radiotherapy. Gynecol Oncol 1990, 36:343-347.
14. Taylor A., Rockall A.G., Reznek R.H., et al. Mapping pelvic lymph nodes: Guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63:1604-1612.
15. Manfredi R., Mirk P., Maresca G., et al. Local-regional staging of endometrial carcinoma: Role of MR imaging in surgical planning. Radiology 2004, 231:372-378.
16. Schwartz L.H., Bogaerts J., Ford R., et al. Evaluation of lymph nodes with RECIST. 1.1. Eur J Cancer 2009, 45:261-267.
17. RECIST, Accessed August 2, 2010. http://recist.com/.
18. Ferenschild F.T., Vermaas M., Verhoef C., et al. Total pelvic exenteration for primary and recurrent malignancies. World J Surg 2009, 33:1502-1508.
19. Steinkamp H.J., Cornehl M., Hosten N., et al. Cervical lymphadenopathy: Ratio of long-to short-axis diameter as a predictor of malignancy. Br J Radiol 1995, 68:266-270.
20. Land R., Herod J., Moskovic E., et al. Routine computerized tomography scanning, groin ultrasound with or without fine needle aspiration cytology in the surgical management of primary squamous cell carcinoma of the vulva. Int J Gynecol Cancer 2006, 16:312-317.
21. Ahuja A., Ying M. Sonography of neck lymph nodes. part II: Abnormal lymph nodes. Clin Radiol 2003, 58:359-366.
22. Moskovic E.C., Shepherd J.H., Barton D.P., et al. The role of high resolution ultrasound with guided cytology of groin lymph nodes in the management of squamous cell carcinoma of the vulva: A pilot study. Br J Obstet Gynaecol 1999, 106:863-867.
23. Esen G. Ultrasound of superficial lymph nodes. Eur J Radiol 2006, 58:345-359.
24. Sohaib S.A., Moskovic E.C. Imaging in vulval cancer. Best Pract Res Clin Obstet Gynaecol 2003, 17:543-556.
25. Hall T.B., Barton D.P., Trott P.A., et al. The role of ultrasound-guided cytology of groin lymph nodes in the management of squamous cell carcinoma of the vulva: 5-year experience in 44 patients. Clin Radiol 2003, 58:367-371.
26. Glazer G.M., Gross B.H., Quint L.E., et al. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol 1985, 144:261-265.
27. Vinnicombe S.J., Norman A.R., Nicolson V., et al. Normal pelvic lymph nodes: evaluation with CT after bipedal lymphangiography. Radiology 1995, 194:349-355.
28. Magnusson A. Size of normal retroperitoneal lymph nodes. Acta Radiol Diagn (Stockh) 1983, 24:315-318.
29. Hricak H., Yu K.K. Radiology in invasive cervical cancer. AJR Am J Roentgenol 1996, 167:1101-1108.
30. Kitajima K., Murakami K., Yamasaki E., et al. Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. AJR Am J Roentgenol 2008, 190:1652-1658.
31. Benedetti-Panici P., Maneschi F., Scambia G., et al. Lymphatic spread of cervical cancer: An anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy. Gynecol Oncol 1996, 62:19-24.
32. Jager G.J., Barentsz J.O., Oosterhof G.O., et al. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 1996, 167:1503-1507.
33. Burke T.W., Levenback C., Tornos C., et al. Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: Results of a pilot study. Gynecol Oncol 1996, 62:169-173.
34. McMeekin D.S., Lashbrook D., Gold M., et al. Nodal distribution and its significance in FIGO stage IIIc endometrial cancer. Gynecol Oncol 2001, 82:375-379.
35. Brown G., Richards C.J., Bourne M.W., et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 2003, 227:371-377.
36. van den Brekel M.W., Castelijns J.A., Stel H.V., et al. Detection and characterization of metastatic cervical adenopathy by MR imaging: Comparison of different MR techniques. J Comput Assist Tomogr 1990, 14:581-589.
37. Yang W.T., Lam W.W., Yu M.Y., et al. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. AJR Am J Roentgenol 2000, 175:759-766.
38. Yousem D.M., Som P.M., Hackney D.B., et al. Central nodal necrosis and extracapsular neoplastic spread in cervical lymph nodes: MR imaging versus CT. Radiology 1992, 182:753-759.
39. van den Brekel M.W., Stel H.V., Castelijns J.A., et al. Cervical lymph node metastasis: Assessment of radiologic criteria. Radiology 1990, 177:379-384.
40. Mitchell D.G., Hill M.C., Hill S., et al. Serous carcinoma of the ovary: CT identification of metastatic calcified implants. Radiology 1986, 158:649-652.
41. Patel S.V., Spencer J.A., Wilkinson N., et al. Supradiaphragmatic manifestations of papillary serous adenocarcinoma of the ovary. Clin Radiol 1999, 54:748-754.
42. Kim S.H., Kim S.C., Choi B.I., et al. Uterine cervical carcinoma: Evaluation of pelvic lymph node metastasis with MR imaging. Radiology 1994, 190:807-811.
43. Yamada I., Yoshino N., Tetsumura A., et al. Colorectal carcinoma: Local tumor staging and assessment of lymph node metastasis by high-Resolution MR imaging in surgical specimens. Int J Biomed Imaging 2009, 2009:659836.
44. Dooms G.C., Hricak H., Moseley M.E., et al. Characterization of lymphadenopathy by magnetic resonance relaxation times: Preliminary results. Radiology 1985, 155:691-697.
45. Vaupel P.W. Blood flow, oxygenation, tissue pH distribution and bioenergetic status of tumors 1994, Hellmich, Belin, Germany.
46. Barentsz J.O., Jager G.J., van Vierzen P.B., et al. Staging urinary bladder cancer after transurethral biopsy: Value of fast dynamic contrast-enhanced MR imaging. Radiology 1996, 201:185-193.
47. Kinkel K., Ariche M., Tardivon A.A., et al. Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: Value of dynamic contrast-enhanced subtraction MR imaging. Radiology 1997, 204:55-63.
48. Fischbein N.J., Noworolski S.M., Henry R.G., et al. Assessment of metastatic cervical adenopathy using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2003, 24:301-311.
49. Laissy J.P., Gay-Depassier P., Soyer P., et al. Enlarged mediastinal lymph nodes in bronchogenic carcinoma: Assessment with dynamic contrast-enhanced MR imaging. Work in progress. Radiology 1994, 191:263-267.
50. Rowley H.A., Grant P.E., Roberts T.P., et al. Imaging. Theory and applications. Neuroimaging Clin N Am 1999, 9:343-361.
51. Lin G., Ho K.C., Wang J.J., et al. Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J Magn Reson Imaging 2008, 28:128-135.
52. Ross B.D., Moffat B.A., Lawrence T.S., et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003, 2:581-587.
53. Charles-Edwards E.M., deSouza N.M. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 2006, 6:135-143.
54. Colagrande S., Carbone S.F., Carusi L.M., et al. Magnetic resonance diffusion-weighted imaging: Extraneurological applications. Radiol Med 2006, 111:392-419.
55. Namimoto T., Yamashita Y., Sumi S., et al. Focal liver masses: Characterization with diffusion-weighted echo-planar MR imaging. Radiology 1997, 204:739-744.
56. Naganawa S., Sato C., Kumada H., et al. Apparent diffusion coefficient in cervical cancer of the uterus: Comparison with the normal uterine cervix. Eur Radiol 2005, 15:71-78.
57. Abdel Razek A.A., Soliman N.Y., Elkhamary S., et al. Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006, 16:1468-1477.
58. Nakai G., Matsuki M., Inada Y., et al. Detection and evaluation of pelvic lymph nodes in patients with gynecologic malignancies using body diffusion-weighted magnetic resonance imaging. J Comput Assist Tomogr 2008, 32:764-768.
59. Ichikawa T., Erturk S.M., Motosugi U., et al. High-B-value diffusion-weighted MRI in colorectal cancer. AJR Am J Roentgenol 2006, 187:181-184.
60. Kim J.K., Kim K.A., Park B.W., et al. Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. J Magn Reson Imaging 2008, 28:714-719.
61. Weissleder R., Elizondo G., Wittenberg J., et al. Ultrasmall superparamagnetic iron oxide: An intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990, 175:494-498.
62. Koh D.M., Brown G., Temple L., et al. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings-initial observations. Radiology 2004, 231:91-99.
63. Narayanan P., Iyngkaran T., Sohaib S.A., et al. Pearls and pitfalls of MR lymphography in gynecologic malignancy. Radiographics 2009, 29:1057-1069.
64. Saksena M., Harisinghani M., Hahn P., et al. Comparison of lymphotropic nanoparticle-enhanced MRI sequences in patients with various primary cancers. AJR Am J Roentgenol 2006, 187:W582-W588.
65. Thoeny H.C., Triantafyllou M., Birkhaeuser F.D., et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009, 55:761-769.
66. Sironi S., Buda A., Picchio M., et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: Detection with integrated FDG PET/CT. Radiology 2006, 238:272-279.
67. Reinhardt M.J., Ehritt-Braun C., Vogelgesang D., et al. Metastatic lymph nodes in patients with cervical cancer: Detection with MR imaging and FDG PET. Radiology 2001, 218:776-782.
68. Choi H.J., Roh J.W., Seo S.S., et al. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: A prospective study. Cancer 2006, 106:914-922.
69. Amit A., Beck D., Lowenstein L., et al. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecol Oncol 2006, 100:65-69.
70. Loft A., Berthelsen A.K., Roed H., et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: A prospective study. Gynecol Oncol 2007, 106:29-34.
71. Bipat S., Glas A.S., van der Velden J., et al. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: A systematic review. Gynecol Oncol 2003, 91:59-66.
72. Kitajima K., Murakami K., Yamasaki E., et al. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol 2009, 19:1529-1536.
73. Bristow R.E., Giuntoli R.L., Pannu H.K., et al. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 2005, 99:294-300.
74. Fanti S., Nanni C., Castellucci P., et al. Supra-clavicular lymph node metastatic spread in patients with ovarian cancer disclosed at 18F-FDG-PET/CT: An unusual finding. Cancer Imaging 2006, 6:20-23.
75. Gontier E., Wartski M., Guinebretiere J.M., et al. 18F-FDG PET/CT in a patient with lymph node metastasis from ovarian adenocarcinoma. AJR Am J Roentgenol 2006, 187:W285-W289.
76. Shreve P.D., Anzai Y., Wahl R.L. Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. Radiographics 1999, 19:61-77.
77. Strauss L.G. Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996, 23:1409-1415.
78. Bhargava P., Zhuang H., Kumar R., et al. Iatrogenic artifacts on whole-body F-18 FDG PET imaging. Clin Nucl Med 2004, 29:429-439.
79. Goerres G.W., Ziegler S.I., Burger C., et al. Artifacts at PET and PET/CT caused by metallic hip prosthetic material. Radiology 2003, 226:577-584.
80. Nakamoto Y., Chin B.B., Cohade C., et al. Artifacts caused by bowel motion. Nucl Med Commun 2004, 25:221-225.
81. Rennen H.J., Corstens F.H., Oyen W.J., et al. New concepts in infection/inflammation imaging. Q J Nucl Med 2001, 45:167-173.
82. Veit P., Ruehm S., Kuehl H., et al. Lymph node staging with dual-modality PET/CT: Enhancing the diagnostic accuracy in oncology. Eur J Radiol 2006, 58:383-389.
83. Kostakoglu L., Agress H., Goldsmith S.J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003, 23:315-340.
84. Schinagl D.A., Hoffmann A.L., Vogel W.V., et al. Can FDG-PET assist in radiotherapy target volume definition of metastatic lymph nodes in head-and-neck cancer?. Radiother Oncol 2009, 91:95-100.
85. Amant F., Cadron I., Fuso L., et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 2005, 98:274-280.
86. Torne A., Puig-Tintore L.M. The use of sentinel lymph nodes in gynaecological malignancies. Curr Opin Obstet Gynecol 2004, 16:57-64.
87. van der Zee A.G., Oonk M.H., de Hullu J.A., et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 2008, 26:884-889.
88. Schneider A. The sentinel concept in patients with cervical cancer. J Surg Oncol 2007, 96:337-341.
89. Sakuragi N. Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer. Int J Clin Oncol 2007, 12:165-175.
90. Selman T.J., Mann C.H., Zamora J., et al. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health 2008, 8:8.
91. Adib T., Barton D.P. The sentinel lymph node: Relevance in gynaecological cancers. Eur J Surg Oncol 2006, 32:866-874.
92. Barwick T., Bencherif B., Mountz J.M., et al. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: A comprehensive evaluation. Nucl Med Commun 2009, 30:908-917.
93. Tsujikawa T., Yoshida Y., Mori T., et al. Uterine tumors: Pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET-initial experience. Radiology 2008, 248:599-605.
94. Wunderbaldinger P. Optical imaging of lymph nodes. Eur J Radiol 2006, 58:390-393.
95. Kim S.K., Choi H.J., Park S.Y., et al. Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients. Eur J Cancer 2009, 45:2103-2109.
96. von Schulthess G.K., Schlemmer H.P. A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 2009, 36:S3-S9.
97. Carrington B.M. Lymph node metastases. Imaging in Oncology 2004, Taylor & Francis, London. J.E. Husband, R.H. Reznek (Eds.).
98. Williams A.D., Cousins C., Soutter W.P., et al. Detection of pelvic lymph node metastases in gynecologic malignancy: A comparison of CT, MR imaging, and positron emission tomography. AJR Am J Roentgenol 2001, 177:343-348.
99. Connor J.P., Andrews J.I., Anderson B., et al. Computed tomography in endometrial carcinoma. Obstet Gynecol 2000, 95:692-696.
100. Zerbe M.J., Bristow R., Grumbine F.C., et al. Inability of preoperative computed tomography scans to accurately predict the extent of myometrial invasion and extracorporeal spread in endometrial cancer. Gynecol Oncol 2000, 78:67-70.
101. Inubashiri E., Hata K., Kanenishi K., et al. Positron emission tomography with the glucose analog [F]-fluoro-2-deoxy-d-glucose for evaluating pelvic lymph node metastasis in uterine corpus cancer: Comparison with CT and MRI findings. J Obstet Gynaecol Res 2009, 35:26-34.
102. Tempany C.M., Zou K.H., Silverman S.G., et al. Staging of advanced ovarian cancer: Comparison of imaging modalities-report from the Radiological Diagnostic Oncology Group. Radiology 2000, 215:761-767.
103. Ricke J., Sehouli J., Hach C., et al. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol 2003, 13:943-949.
104. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
105. Rockall A.G., Sohaib S.A., Harisinghani M.G., et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005, 23:2813-2821.
106. Will O., Purkayastha S., Chan C., et al. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: A meta-analysis. Lancet Oncol 2006, 7:52-60.